bioAffinity Technologies, Inc. BIAF 深 沪
已收盘 10-02 16:00:00 美东时间
6.055
-0.090
-1.46%
华盛通- 最 高6.235
- 今 开6.06
- 成交量 15.46万股
- 最 低 5.90
- 昨 收 6.145
- 总市值 363.75万
- 52周最高 80.70
- 市盈率 静 --
- 换手率 25.74%
- 52周最低 4.56
- 委 比 94.17%
- 总股本 60.07万
- 历史最高 6997.50
- 量 比 0.69
- 振 幅 5.45%
- 历史最低 4.878
- 每 手 1
- 风险率 14.16%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Hong Kong Intellectual Property Department Grants Patent For bioAffinity’s Proprietary Platform Technology For Predicting Likelihood Of Lung Cancer Using Flow Cytometry And Fluorescent Markers To Characterize Cell Populations In Sputum
Dual patent protection in Hong Kong and China strengthens CyPath Lung’s positioning to enter Asian market Asia accounts for nearly two-thirds of lung cancer cases worldwide bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)),a biotechnology company developing noninvasive healthcare solutions for th...
09-17 20:04
Why iSpecimen Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket
Shares of iSpecimen Inc (NASDAQ:ISPC) rose sharply in pre-market trading after the company announced plans to acquire Foldlab AI assets for $4.5 million, including AI models, software and intellectual property. iSpecimen shares jumped 27.9% to $1.97 in pre-market trading. Here are some other stocks ...
09-08 16:44
bioAffinity Technologies Announces 1-For-15 Reverse Stock Split, Effective Aug. 24
bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it will effect a 1-for-15 reverse split of its common stock. Commencing with the opening of trading on the Nasdaq Capi...
08-20 20:04
bioAffinity Enters Into Distribution Agreement With AvMEDICAL Expanding bioAffinity's Commercial Reach Through AvMEDICAL's Existing Sales Team
New partner’s national sales force will market CyPath Lung to federal healthcare agencies, including VA medical centers nationwide Agreement significantly expands bioAffinity's commercial reach through AvMEDICAL's existing sales team Service-Disabled Veteran-Owned AvMEDICAL provides access to estab...
08-18 20:06
bioAffinity Technologies Q2 EPS $(0.64) Beats $(2.40) Estimate, Sales $1.511M Beat $1.483M Estimate
bioAffinity Technologies (NASDAQ:BIAF) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate of $(2.40) by 73.33 percent. This is a 87.45 percent increase over losses of $(5.10) per share from the same period last year. The company reported quarterly sales of $1.51...
08-07 20:11
bioAffinity, Pictor Collaborate To Integrate Flow Cytometry And Proteomic Analysis Platform To Analyze Immune Cell Populations And Cytokine Profiles Related To Airway Inflammation
Collaboration increases laboratory throughput and reduces costs for personalized testing for asthma and COPD, which affect more than 40 million Americans and 650 million people worldwide Global asthma and COPD therapeutics market projected to exceed $108 billion in 2026 and $155 billion by 2030, dri...
07-22 20:11
BioAffinity Technologies Announces 200% Sales Growth YoY For CyPath Lung Cancer Diagnostic
BioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, today announced continued acceleration in commercial sales for CyPath® Lung, its noninvasive lung ca...
07-07 20:49
bioAffinity To Present Preclinical Findings For Therapeutic Approach That Uses siRNAs That Kill Squamous And Basal Skin Cancer Cells In Vitro At 2026 RNA Therapeutics Symposium
Research suggests a potential topical treatment for common skin cancers, squamous cell and basal cell carcinoma Findings will be presented at 2026 RNA Therapeutics Symposium June 24-26 bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company advancing early-stage cancer diagnost...
06-22 20:07
bioAffinity Technologies Prices $3.2M Offering Of 4M Shares (Or Pre-funded Warrants) At $0.80/Share ($0.793/Warrant)
bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, today announced that it has priced a Public Offering of securities as described below for aggregate ...
06-17 21:26
bioAffinity Receives Mexican Institute Of Industrial Property Allowance For A Patent Application Regarding Methods Of Predicting The Likelihood Of Lung Cancer Using Flow Cytometry
Upon issuance, the Mexican patent application will protect the use of defined antibodies and the porphyrin TCPP to label cell populations in sputum and the use of flow cytometry to determine the presence of lung cancer
05-27 20:07
